Navigating the clinical development landscape for oncolytic viruses and other cancer therapeutics: no shortcuts on the road to approval [0.03%]
溶瘤病毒及其他抗癌药物临床开发格局的形成：通向批准之路并无捷径可走
Caroline J Breitbach,Tony Reid,James Burke et al.
Caroline J Breitbach et al.
Chemotherapy remains a common mode of anticancer treatment even though in most cancer indications the therapeutic approach is not effective and ultimately associated with the onset of chemoresistance. A better understanding of genetic diffe...
Crosstalk between TNF and glucocorticoid receptor signaling pathways [0.03%]
肿瘤坏死因子与糖皮质激素受体信号通路的相互作用
Tom Van Bogaert,Karolien De Bosscher,Claude Libert
Tom Van Bogaert
TNF is a Janus-faced protein. It possesses impressive anti-tumor activities, but it is also one of the strongest known pro-inflammatory cytokines, which hampers its use as a systemic anti-cancer agent. TNF has been shown to play a detriment...
Recent advances in the development of oncolytic viruses as cancer therapeutics. Foreword [0.03%]
溶瘤病毒作为癌症治疗的研究新进展。前言
John Bell,David Kirn
John Bell
Hisayuki Nomiyama,Naoki Osada,Osamu Yoshie
Hisayuki Nomiyama
Chemokines play an important role in orchestrating cell recruitment and localization in both physiological and pathological conditions. More than 44 ligands have been identified in the human genome. A significantly different set of chemokin...
High avidity cytokine autoantibodies in health and disease: pathogenesis and mechanisms [0.03%]
高亲和力细胞因子自身抗体在健康与疾病中的发病机制及作用模式
Masato Watanabe,Kanji Uchida,Kazuhide Nakagaki et al.
Masato Watanabe et al.
Numerous reports have documented the presence of autoantibodies working against naturally occurring cytokines in humans in health and disease. In most instances, their physiological and pathophysiological significance remains unknown. Howev...
Jeffrey Wojton,Balveen Kaur
Jeffrey Wojton
Interactions between tumor cells and their microenvironment have been shown to play a very significant role in the initiation, progression, and invasiveness of cancer. These tumor-stromal interactions are capable of altering the delivery an...
Oncolytic viruses and histone deacetylase inhibitors--a multi-pronged strategy to target tumor cells [0.03%]
溶瘤病毒和组蛋白去乙酰化酶抑制剂——多管齐下的肿瘤细胞靶向策略
Thi Lien-Anh Nguyen,Marnie Goodwin Wilson,John Hiscott
Thi Lien-Anh Nguyen
Oncolytic viruses (OVs) have shown promise as cancer therapeutics in pre-clinical and clinical testing; however, it is unlikely that OVs will constitute a stand-alone treatment. Histone deacetylase inhibitors (HDIs) represent a class of ant...
James Burke
James Burke
Approximately 50,000 cases of superficial bladder cancer are diagnosed annually in the United States. Immunotherapy utilizing intravesical BCG is the most effective standard therapy for superficial transitional cell carcinoma of the bladder...
James M Burke
James M Burke
Monoclonal antibody therapy for cancer has significantly altered the natural history of several common cancers. This success was attained only after many years of failure to understand the technical limitations of antibody therapy. In order...
Double trouble for tumours: exploiting the tumour microenvironment to enhance anticancer effect of oncolytic viruses [0.03%]
肿瘤微环境促进溶瘤病毒抗癌效应的研究进展及其机制探讨
Naomi De Silva,Harold Atkins,David H Kirn et al.
Naomi De Silva et al.
Oncolytic viruses (OVs) are selected based on their ability to eliminate malignancies by direct infection and lysis of cancer cells. Originally, OVs were designed to target malignancies by taking advantage of the defects of cancer cells obs...